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Abstract: Chronic Migraine (CM) is a disabling neurologic condition with a severe impact on 
functioning and quality of life. Successful therapeutic management of patients with CM is complex, 
and differences in therapeutic response could be attributable to genetically determined factors, 
sensitivity to pharmacological treatment, psychosocial and relational factors affecting the patient’s 
compliance and approach on the therapeutic treatment. The aim of this prospective observational 
study was to explore self-efficacy, coping strategies, psychological distress and headache-related 
disability in a cohort of 40 patients with CM (mean age: 46.73; standard deviation 13.75) treated with 
OnabotulinumtoxinA and the relationship between these clinical and psychological aspects and 
acute medication consumption during OnabotulinumtoxinA prophylactic treatment. Patients 
presented an overall significant reduction in the Headache Index (HI) (p < 0.001), HI with severe 
intensity (p = 0.009), and total analgesic consumption (p = 0.003) after the prophylactic treatment. 
These results are in line with the literature. Despite this, higher nonsteroidal anti-inflammatory 
drugs consumption was associated with higher psychological distress, higher HI with severe and 
moderate intensity, and worse quality of life. Conversely, triptans consumption was correlated with 
HI of mild intensity, and problem-focused coping strategies. To conclude, the psychological profile, 
and in particular, the psychological distress and specific coping strategies might influence the self-
management of acute medication. 
Keywords: psychological distress; pain; disability; Anti-Inflammatory Agents Non-Steroidal; drugs 
Key Contribution: Psychological distress and abnormal coping strategies might influence the self-
management of acute medication in patients with chronic migraine undergoing 
OnabotulinumtoxinA prophylactic treatment. 
 
1. Introduction 
Chronic Migraine (CM) is a disabling neurologic condition with a severe impact on functioning 
and quality of life [1]. It accounts for about one-third of chronic headaches affecting 1–2% of the 
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general population [1]. According to the Classification ICHD-III (beta), patients with CM experience 
headache at least 15 days per month for more than three consecutive months, with at least eight days 
per month being classified as migraine attacks or headaches that respond to migraine-specific 
medications [2]. This definition has two main implications: (i) it takes into account the presence of 
migraine attacks of different severity (i.e., lighter attacks) without neurogenerative hallmarks that 
can resemble tension-type headache; (ii) it introduces new diagnostic criteria which also include 
patients with overuse of acute migraine medications [1].  
The physiopathology of CM is not clearly understood [1,3]. However, multifactorial 
pathophysiology in which susceptibility to attack-triggering stimuli contribute to the threshold for 
the generation of migraine attack has been suggested [1]. As far as the neurogenic inflammation of 
meninges is considered, high levels of cytokines and neuropeptides are released during migraine 
attacks. They activate specific neural pathways that transmit pain to the trigeminovascular and 
vegetative system nuclei. The release of these neuropeptides induces vasodilatation in meningeal 
areas and neurogenic inflammation. Repeated episodes of trigeminovascular system activation 
sensitize peripheral nociceptors and central pain pathways leading to central sensitization [4]. Central 
and peripheral nociceptors sensitization is assumed to be one of the key mechanisms of migraine 
chronification [1]. Increased migraine attack frequency along with insufficient acute pain relief lead 
to sensitization, which further lower migraine attack threshold [1]. 
With this perspective, migraine is conceptualized as a continuum from episodic to chronic 
forms, whereby “chronic” indicates severity or patient-specific symptomatic burden, as opposed to 
the duration of disease [5]. On the one hand, many contributing factors can decrease the sensory 
threshold for the generation of migraine attacks (i.e., genetic predisposition, female sex, obesity, 
depression, and stressful life events). An ineffective acute treatment and overuse of acute migraine 
medication predispose to migraine chronification. Conversely, factors related to behaviour and 
lifestyle (i.e., higher education, being married, social support, exercise and stress management) have 
been reported as protective factors that can heighten the threshold and thereby reduce the frequency 
of migraine attacks. The evidence that about 26% of patients with CM go into remission within two 
years of chronification emphasized the importance of early and multidisciplinary management [1].  
Successful management of patients with CM is complex and represents a challenge for primary 
care as well as for specialist, as in other chronic pain conditions [3,6]. Particularly pertinent for the 
management of CM is the systematic monitoring of migraine symptoms using the headache diary to 
have an accurate reporting of headache frequency and intensity [6]. From a clinical point of view, this 
approach allows estimating the Headache Index (HI) as a measure of disease severity and impact in 
the quality of life. In the research field, having a comparable index of disease severity permits to 
compare treatment effects among studies. 
It has been well established that the treatment of acute attacks and prophylactic management 
play a crucial role. However, each subject does not have the same therapeutic response [3]. The reason 
for these different outcomes should be searched for in different domains that could be attributable to 
genetically determined factors interfering with the aetiology, tendency to the chronification, 
sensitivity to pharmacological treatment, psychosocial and relational factors affecting the patients’ 
compliance and approach to the treatment [1,3]. 
As far as prophylactic management, OnabotulinumtoxinA is the only prophylactic treatment 
specifically approved to reduce the frequency and the severity of migraine attacks [7–9]. In 2010, it 
was approved for the treatment of chronic migraine after two large-scale double-blind, randomized 
placebo-controlled trials which supported its safety and effectiveness [7–9]. Recent guidelines 
recommended OnabotulinumtoxinA as an effective and well-tolerated treatment of CM and 
provided recommendations for its use [10]. However, future studies on the treatment of CM using 
OnabotulinumtoxinA are needed to improve the management of this disabling disorder [10]. The 
mechanism of action of OnabotulinumtoxinA in central neuropathic pain has been described in detail 
in the literature [11]. The potential action on sensitized nociceptive afferents is intriguing. In rats, 
OnabotulinumtoxinA was shown to decrease sensitization on nociceptive meningeal C-fibers [12]. 
The hypothesis is that OnabotulinumtoxinA can directly decrease the amount of calcitonin gene-
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related peptide released from trigeminal neurons [13] and thus reduce neurogenic inflammation and 
central sensitization [13]. More recently, novel therapeutic options aimed at inhibiting calcitonin 
gene-related peptide signaling has attracted growing interest in the pharmacological research on 
migraine. Human monoclonal antibodies have been approved for the preventive treatment in 
patients with episodic and chronic migraine, reporting positive effects [14–16]. 
Nevertheless, positive results should rely on the management by the patient of acute medication. 
For example, the treatment of acute attacks is prescribed by the specialist but self-managed by the 
patient according to the intensity and the features of each migraine attack. They include the use of 
different categories of drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and triptans, 
usually in polytherapy. The prophylactic treatment through OnabotulinumtoxinA reduces the 
headache symptoms and common comorbidities, including depression and anxiety [17–22]. Briefly, 
these studies reported that OnabotulinumtoxinA alleviated the severity and frequency of migraine 
attacks and these effects were associated with improvements in depression and anxiety. These 
improvements might be a consequence of the CM relief. However, the molecular mechanisms are 
unknown. 
Note that psychological factors and pain coping styles might influence acute medication intake 
in terms of quantity and type (i.e., NSAIDs and triptans) [17,23]. Literature has suggested, for 
instance, a relationship between migraine episode recurrence and maladaptive coping strategies [24]. 
Gunel and Akkaya reported that patients with migraine tend to seek social support lesser than 
healthy controls [25]. Bagianti et al. (2014) reported in their retrospective analysis on patients with 
chronic migraine and medication overuse that at one-year follow-up patients who did relapse into 
medication overuse reported increased anxiety and perpetuation of severe dependency-like 
behaviours. Conversely, patients who did not relapse had clinical improvements with decreased 
depressive symptoms and dependency-like behaviour, although reporting a low internal pain control 
[26]. More recently, D’Amico et al. (2015) found that disability and quality of life were moderately or 
little related to clinical and psychological factors in patients with CM and medication overuse [27]. 
The main limitations of these studies are the lack of homogeneity about the prophylactic 
treatment and, where it was provided, considerable heterogeneity in the OnabotulinumtoxinA 
injection paradigm (and dose). Moreover, the lack of assessment of acute medication consumption, 
and the evaluation of mainly depression and anxiety should be outlined. 
So far, no studies exploring the influence of psychological distress and coping strategies on the 
OnabotulinumtoxinA treatment effects and the acute medication consumption in patients with CM 
have been reported.  
This study aimed to explore self-efficacy, coping strategies, psychological distress and headache-
related disability in a cohort of patients with CM treated with OnabotulinumtoxinA and the 
relationship between these clinical and psychological aspects and acute medication consumption 
during OnabotulinumtoxinA prophylactic treatment. 
We expect that the relative contribution of psychological factors would vary among patients 
undergoing the same prophylactic treatment and would interfere with the acute medication 
consumption. Improved understanding of the association between these factors might lead us to 
more effective management for this disabling neurologic condition. 
2. Results 
2.1. Demographic and Clinical Carachteristics of Patients with CM 
Seventy-two patients attending the Neurorehabilitation Unit were screened for eligibility. 
Eighteen patients were excluded because involved in other research activities. Fifty-four patients 
were considered eligible. Fourteen patients were excluded because of the lack of consent to perform 
the psychological assessment and incomplete diary in the 12 weeks before the enrolment. Therefore, 
40 patients with CM (mean age: 46.73 years; SD: 13.75) were enrolled. 
The majority of patients was women (92.5%), most of whom were contraceptive consumers 
(89.2%) and menopausal (59.5%). Most patients were both smoker (85%) and alcohol consumers 
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(87.5%); a large percentage of them was already under pre-study Headache Prophylaxis therapy 
(60%) and did not respond to acute headache medication (65%). The majority of patients were not 
taking antidepressants or anxiolytic therapy (65%). Patients’ demographic and clinical features are 
reported in detail in Table 1. 
Table 1. Patients’ demographic and clinical features. 
Demographic and Clinical Features  N (%) 
Age (years) (Mean, SD) 46.73 (13.75) 
Sex (female) 37 (92.5%) 
Body Mass Index 23.62 
Sleep  
regular  
irregular  
regular with drugs 
17 (42.5%)  
15 (37.5%)  
8 (20%) 
Familiarity with the headache (yes) 25 (62.5%) 
Onset  
pre-adolescence  
adolescence 
adult age 
11 (27.5%) 
13 (32.5%) 
16 (40%) 
Type of Pain  
constrictive 
pulsating 
both 
17 (42,5%) 
17(42.5%) 
4 (10%) 
Presence of aura (yes) 10 (25%) 
Pre-study Headache Prophylaxis therapy (non-use) 16 (40%) 
Sport Activity (yes)  18 (45%) 
Smoker (yes) 34 (85%) 
Alcohol consumer (yes) 35 (87.5%) 
Contraceptive consumer (yes)* 33 (89.2%) 
Menopause (yes)* 22 (59.5%) 
Medical comorbidities (present) 24 (60%) 
Acute Headache medicine responsiveness (yes) 14 (35%) 
Antidepressants or Anxiolytics consumer (yes) 14 (35%) 
On a controlled diet 7 (17.5%) 
Number of Detoxification Treatments  
None 
One 
two 
19 (47.5%) 
18 (45%) 
3 (7.5%) 
Legend: N, number; %, percentage; SD, standard deviation. 
2.2. Headache Index (HI) and Headache-Related Disability Scores during Treatment Phases 
There was an overall significant reduction in the HI (p < 0.001). Similarly, the HI with severe 
intensity (p = 0.009), and total analgesic consumption (p = 0.003) decreased significantly over time. 
Post hoc analysis resulted in a significant reduction in the HI (T1: p < 0.001; T2: p = 0.008), in the HI 
with severe intensity at T2 (p = 0.021) and in total analgesic consumption at T2 (p = 0.017). HI with 
moderate and mild intensity progressively decreased, albeit not significantly. 
Quality of life (HIT 6) showed an improvement over time, albeit not statistically significant. At 
T0, the high HIT-6 mean score (above 60 points) demonstrated the severe impact of CM symptoms 
on quality of life. At T2, the HIT-6 score decreased by −2.95 points indicating a meaningful 
improvement in the quality of life (within-person MCI: −2.5 points) and a substantial reduction of 
symptoms severity. The NSAIDs and Triptans consumption progressively decreased over time, albeit 
not significantly. Headache Index and Analgesic Daily Consumption are reported in Table 2.  
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Table 2. Headache Index and Analgesic Daily Consumption. 
Outcomes 
T0 
Mean (SD) 
n = 40 
T1 
Mean (SD) 
n = 35 
T2 
Mean (SD) 
n = 30 
Friedman Test  
p-value 
Wilcoxon Test for Paired Data 
HI 0.44 (0.25) 0.37 (0.24) ** 0.36 (0.24) ** < 0.001 
HI Severe Intensity  0.92 (1.41) 0.59 (1.09) 0.56 (1.11) * 0.009 
HI Moderate Intensity 0.98 (1.39) 0.95 (1.48) 0.78 (1.05) 0.20 
HI Mild intensity 1.22 (2.39) 1.36 (2.08) 0.97 (2.20) 0.75 
HIT-6 61.62 (8.42) 61.48 (7.57) 58.67 (10.35) 0.06 
Total Analgesics Consumption 0.41 (0.45) 0.33 (0.35) 0.24 (0.21) ** 0.003 
NSAIDs Consumption 0.22 (0.39) 0.17 (0.35) 0.11 (0.21) 0.09 
Triptans Consumption 0.18 (0.17) 0.16 (0.17) 0.12 (0.11) 0.10 
Legend: SD, standard deviation; HI, Headache Index; HIT-6, Headache Impact Test; N, number; 
NSAIDs, nonsteroidal anti-inflammatory drugs; ** p ≤ 0.01 Wilcoxon Test for paired data versus T0; * 
p ≤ 0.05 Wilcoxon Test for paired data versus T0. 
2.3. Psychological Characteristics of Patients with CM 
Self-efficacy, Coping Strategies and Disability are reported in Table 3. As regards coping 
strategies (COPE) the mean score of the sample indicates that the majority of patients included in our 
study were comparable to those reported in the Italian validation study of COPE scale [28]. The mean 
value of the self-efficacy (GSE) scale is in line with the previous value reported by D’Amico and 
collaborators in a sample of chronic migraine patients with medication overuse [27]. Conversely, the 
average psychological distress global score (GSI) was higher than 0.57, which has been considered a 
cut-off value for psychological dysfunction [29,30]. The majority of patients (85%) reported a CM 
related severe disability at T0, as measured by the Migraine Disability Assessment (MIDAS). 
Table 3. Psychological distress, Self-efficacy, Coping Strategies and Disability. 
Outcomes 
T0* 
Mean (SD) 
  
General Symptoms Intensity (GSI) 0.71 (0.48) 
General self-efficacy scale (GSE) 28.45 (4.9) 
Coping style: Social support (COPE-SS) 29.98 (6.77) 
Coping style: Avoidance Strategies (COPE-AS) 23.97 (5.15) 
Coping style: Positive Attitude (COPE-PA) 29.65 (6.30) 
Coping style: Problem Oriented (COPE-PO) 30.60 (5.72) 
Coping style: Turning to Religion (COPE-TR) 22.07 (5.01) 
  
MIDAS total score  65.67 (61.12) 
MIDAS item C headache frequency 39.37 (24.91) 
MIDAS item D pain intensity 6.37 (1.61) 
  
MIDAS Disability Categories n, % 
Low to Moderate Disability (score < 21) 8 (20) 
Severe Disability (score ≥ 21)  32 (80) 
Legend: *, n = 40; SD, standard deviation; n, number; %, percentage; GSI, General Symptoms Intensity; 
GSE, Perceived Self-efficacy; COPE, coping style; SS, Social support; AS, Avoidance Strategies; PA, 
Positive attitude; PO, Problem Oriented; TR, turning to religion; MIDAS, Migraine Disability 
Assessment.  
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2.4. Correlation between Clinical Outcomes and Psychological Profile 
There was a positive correlation between the headache-related disability and the total analgesic 
consumption (rs = 0.336, p =0.034), the HI (rs = 0.547, p = 0.003), the HI with severe intensity (rs = 0.379, 
p = 0.024) and quality of life (rs = 0.464, p =0.003).  
In general, a higher analgesic consumption was associated with higher HI (rs = 0.547, p < 0.001). 
However, NSAID consumption was positively correlated with higher HI (rs =0 .489, p = 0.001) and 
with severe intensity (rs = 0.343, p = 0.037), while triptans consumption was correlated with HI of mild 
intensity (rs = −0.390, p = 0.017). 
At T0, there was a positive correlation between psychological distress (GSI) and NSAIDs 
consumption, HI with severe intensity and headache-related disability (HIT-6). Higher positive 
attitude (COPE-PA) correlated with higher analgesic consumption. Similarly, there was a positive 
correlation between problem-focused strategies (COPE-PO) and the total analgesic and triptans 
consumption. Higher perceived social support (COPE-SS) positively correlated with HI with mild 
intensity (Table 4a and Figure 2).
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Table 4a. Spearman correlation between psychological variables and clinical profile at T0. 
Outcomes Total AC NSAIDs C Triptans C HI HI Severe HI Mod HI Mild HIT-6 
GSI 0.262 (0.10) 0.410 (0.009) ** −0.151 (0.351) 0.23 (0.159) 0.438 (0.007) ** 0.170 (0.315) 0.027 (0.875) 0.394 (0.012) * 
GSE −0.09 (0.581) −0.245 (0.128) 0.111 (0.494) 0.072 (0.661) −0.170 (0.313) 0.028 (0.87) 0.037 (0.826) −0.118 (0.469) 
COPE-SS 0.03 (0.856) −0.106 (0.515) 0.107 (0.509) −0.175 (0.279) 0.187 (0.268) −0.246 (0.142) −0.43 (0.008) ** 0.049 (0.764) 
COPE-AS −0.027 (0.871) 0.244 (0.129) −0.189 (0.242) 0.240 (0.135) 0.257 (0.124) 0.042 (0.804) 0.020 (0.908) 0.174 (0.282) 
COPE-PA 0.356 (0.024) * 0.008(0.961) −0.260 (0.105) 0.092 (0.572) −0.230 (0.127) −0.166 (0.325) −0.244 (0.146) −0.041 (0.80) 
COPE-PO 0.354 (0.025) * −0.04(0.807) 0.329 (0.038) * −0.018 (0.913) −0.257 (0.125) −0.283 (0.09) −0.306 (0.066) −0.287 (0.073) 
COPE-TR −0.130 (0.422) −0.173(0.285) 0.181 (0.265) 0.109 (0.504) 0.076 (0.657) 0.022 (0.899) −0.219 (0.193) 0.183 (0.258) 
Legend: A, analgesic; C, consumption; HI, Headache Index; Mod, moderate; HIT-6, Headache Impact Test; GSI, General Symptoms Intensity; GSE, Perceived Self-efficacy; 
COPE, coping style; SS, Social support; AS, Avoidance Strategies; PA, Positive attitude; PO, Problem oriented; TR, turning to religion. Results are displayed as rs (p value); 
rs, Spearman’s correlation coefficient; *, significant at p ≤ 0.05; **, significant at p ≤ 0.01.
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Figure 1. Changes in triptans consumption and psychological distress and avoiding strategies. Panels 
A (upper): Abscissa indicates the change in triptans consumption between T1 and T0. Ordinate 
indicates psychological distress (GSI). Panel B (lower): Abscissa indicates the change in triptans 
consumption between T1 and T0. Ordinate indicates avoidance strategies. 
Changes in pharmacological intake showed that higher psychological distress (GSI) correlated 
with higher triptans consumption at T1 and T2. When considering the GSI cut-off (0.57), patients 
without psychological dysfunction (GSI values < 0.57) reported a reduction in the triptans 
consumption while patients with psychological disfunction (GSI ≥ 0.57) increased the triptans 
consumption (Figure 2). 
Avoidance strategies (COPE-AS) were positively associated with higher total analgesic 
consumption and higher triptans consumption at T1 and T2. Conversely, higher problem-focused 
approach (COPE-PO) related to a reduction in the total analgesic and NSAIDs consumption at T2. 
Turning to religion (COPE-SS) was positively associated with total analgesic consumption. Table 4b.
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Table 4b. Spearman correlation between psychological variables and change in the acute medication consumption and headache indices during the study. 
Outcomes Total AC 
T1-T0 
Total AC 
T2-T0 
NSAID C 
T1-T0 
NSAID C 
T2-T0 
Triptans C 
T1-T0 
Triptans C  
T2-T0 
HI  
T1-T0 
HI 
T2-T0 
GSI 0.204(0.239) 0.198(0.303) −0.042(0.811) −0.030(0.878) 0.448 **(0.007) 0.515 **(0.004) 0.039(0.826) −0.032(0.869) 
GSE −0.191(0.271) −0.287(0.131) −0.287(0.094) −0.157(0.417) −0.089(0.609) −0.328(0.083) 0.070(0.690) −0.016(0.936) 
COPE-SS −0.058(0.740) −0.074(0.701) 0.250(0.148) 0.006(0.974) −0.031(0.862) −0.015(0.939) 0.033(0.849) −0.081(0.675) 
COPE-AS 0.347 *(0.041) 0.343(0.069) −0.064(0.717) 0.021(0.913) 0.519 **(0.001) 0.576 **(0.001) 0.204(0.241) 0.100(0.605) 
COPE-PA −0.075(0.669) −0.128(0.510) −0.051(0.771) −0.107(0.579) −0.018(0.917) −0.041(0.833) −0.104(0.553) −0.242(0.205) 
COPE-PO −0.288(0.094) −0.553 **(0.002) −0.096(0.583) −0.387 *(0.038) −0.089(0.612) −0.295(0.120) 0.036(0.839) −0.102(0.599) 
COPE-TR 0.241(0.162) 0.441 *(0.017) −0.170(0.328) 0.280(0.141) −0.035(0.841) 0.202(0.294) −0.227(0.190) 0.263(0.168) 
Legend: A, analgesic; C, consumption; HI, Headache Index; Mod, moderate; HIT-6, Headache Impact Test; GSI, General Symptoms Intensity; GSE, Perceived Self-efficacy; 
COPE, coping style; SS, Social support; AS, Avoidance Strategies; PA, Positive attitude; PO, Problem oriented; TR, turning to religion. T0, T1 and T2 are displayed in Figure 
1. Results are displayed as rs (p value); rs, Spearman’s correlation coefficient; *, significant at p ≤ 0.05; **, significant at p ≤ 0.01.
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3. Discussion 
To the best of our knowledge, this study is the first one exploring the pharmacological habitus 
and the clinical and psychological aspects of CM undergoing the same prophylactic treatment by 
using OnabotulinumtoxinA. Strengths in the methodology of this study include the fact that all 
patients underwent the same CM management, consisting of the same specialist giving the diagnosis 
and pharmacological indication and the same specialist giving the OnabotulinumtoxinA injection 
according to international guidelines protocol [10]. 
The main finding of this prospective observational study was that despite the global reduction 
in the headache symptoms and acute medication intake, higher NSAIDs consumption was associated 
with higher psychological distress, higher HI with severe intensity, and worse quality of life. 
Conversely, triptans consumption was correlated with HI of mild intensity, and high problem-
focused coping strategies. These two different patterns of medication use suggest that psychological 
distress and specific coping strategies might influence the self-management of acute medication.  
Additionally, we explored the relationship between psychological aspects and clinical and 
medication outcomes at follow up. With progress on the prophylactic treatment, pharmacological 
treatment remained related to the psychological profile. In particular, the reduction in the triptans 
consumption was related to lower psychological distress and lower avoidance coping strategies. 
Conversely, lower problem-focused coping strategies were related to an increase in NSAIDs and 
analgesic consumption, but only at T2. The overall trend in the reduction of the number of days with 
migraine was similar to that reported in OnabotulinumtoxinA trails. The OnabotulinumtoxinA was 
first used in the treatment of movement disorders and focal spasticity in patients with Central 
Nervous System damage. Early observations in cervical dystonia suggested that besides the 
anticholinergic effect, OnabotulinumtoxinA may decrease pain before muscle relaxation [12]. A 
report of pain relief in patients with migraine pain, and without muscle hyperactivity, paved the way 
to the potential OnabotulinumtoxinA mechanism in reducing chronic pain syndromes. Finally, two 
large-scale double-blind, randomized placebo-controlled trials supported its safety and effectiveness 
in patients with CM [7–9]. Briefly, the standardized PREEMPT (Phase III Research Evaluating 
Migraine Prophylaxis Therapy) injection protocol consists of OnabotulinumtoxinA injection at a 
minimum dose of 155U OnabotulinumtoxinA into seven specific muscle groups (fixed-dose 
paradigm): Frontalis, Corrugator, Procerus, Temporalis, Cervical Paraspinal Muscle group, 
Occipitalis, Trapezius. A total dose up to 195U was approved for additional injections into the 
temporalis, occipitalis and trapezius muscles according to a “follow-the-pain” paradigm [31–33]. 
Results from the PREEMPT trials have established that OnabotulinumtoxinA is effective in 
controlling the pain in patients with CM with or without acute medication overuse up to 56 weeks 
[7–9]. More recently, the long-term phase IV study (COMPEL) has reported the efficacy and 
tolerability of OnabotulinumtoxinA over two years, in which patients received up to nine treatment 
cycles. These findings have been confirmed by several real-world clinical practice studies from 
Europe, including the prospective multinational REPOSE and CM-PASS studies [34,35]. 
The percentage of reduction in the HI at T1 (−16%) and T2 (−18.8%) could be considered beyond 
the responder rate reported in the literature. It might depend on the fact that patients were 
undergoing prophylactic treatment using OnabotulinumtoxinA since at least three injections, and 
thus, they were not naïve patients to the treatment. Therefore, treatment effects should be considered 
as additional effects obtained after prolonged OnabotulinumtoxinA injection. Interestingly, the 
percentage of reduction in the total number of analgesic consumptions was around 19% at T1 and 
approaching 42% at T2. It might depend on how the headache diary was compiled: data were self-
reported and could be influenced by the patient’s mood, with the risk of overvaluing headache 
symptoms. Conversely, the number of medication intake should be considered a more objective 
measure of therapy efficacy. 
Patients reported severe adverse impact on the quality of life and disability related to CM and, 
notwithstanding the definite reduction of HIT6 observed over time, the adverse effect was still 
relevant. Moreover, although examining the prevalence of psychological disorders in the sample was 
out of the scope of this study, it is noteworthy that approximately a third of patients declared the use 
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of antidepressant or anxiolytic medications and the mean GSI score suggested a high level of 
psychological distress at enrolment. This result seems in line with the literature, which highlights a 
high prevalence of psychological disorders, particularly depression and anxiety, and even sub-
threshold psychological symptoms in patients with CM [1,27,36–41]. The disability picture emerging 
from those data confirms the relevance of assessing psychological distress, psychiatric comorbidities 
and quality of life in patients with CM when attending healthcare services for receiving prophylactic 
treatment using OnabotulinumtoxinA. Indeed, psychological distress is often under-recognized and 
untreated, and patients with migraine often do not report psychological distress or psychiatric 
symptoms in the clinical encounter [42]. The continuity of OnabotulinumtoxinA treatment 
administration overtime for several months might contribute to easing the assessment of 
psychological distress of patients and referring them, if needed, to psychological treatment. This 
longitudinal approach should be introduced as a future direction of our study in order to explore the 
effect of OnabotulinumtoxinA on psychopathology course both alone and combining botulinum and 
effective psychological approaches [43–45]. 
Higher psychological distress resulted associated both with higher headache-related negative 
impact and HI severity, confirming the findings reported by previous literature on the relationship 
between comorbid depression and anxiety symptoms with adverse migraine outcomes [22]. 
Additionally, even if psychological distress resulted higher in patients with medication overuse, our 
findings show a specific association with NSAIDs consumptions at baseline, while patients with 
higher psychological distress reported higher triptans consumptions over time. To the best of our 
knowledge, this specific relationship between NSAIDs or triptans consumption and psychological 
distress has not been studied yet. However, preliminary studies in stressed rats with depression and 
pseudodementia like symptoms showed that the administration of triptans, in particular, 
zolmitriptan, might act as a 5-HT-1B agonist and therefore decrease depression symptoms [46]. 
Our sample reported lower perceived self-efficacy than Italian validation study data, according 
to results reported by D’Amico et al. (2015) [27]. Self-efficacy is conceived as the belief that one can 
successfully engage in actions to achieve the desired outcome [47,48]. This psychological process has 
been recognized to interact with headache treatment outcomes. Higher levels of self-efficacy are 
associated with greater adherence to preventive and acute pharmacological treatments [48]. 
Conversely, low self-efficacy is a prognostic indicator for negative outcome in chronic headache [49]. 
In our study, perceived self-efficacy did not significantly correlate with medication use, HI and HIT-
6 scores both at baseline and with progress on the prophylactic treatment. Albeit not significant from 
a statistical point of view, patients with NSAIDs consumption reported a negative correlation with 
the perceived self-efficacy as if they felt to be less able to manage acute attacks. In the literature, self-
efficacy has been examined in a paucity of studies on CM patients; however, this psychological 
dimension has been suggested as critical for headache management and disability [27,48,50]. Indeed, 
the defective patients’ confidence in their ability to achieve personal goals along with depressive 
symptoms might affect the success of therapeutic strategies to manage their acute medication intake. 
Therefore, self-efficacy might represent a psychosocial aspect of interest, which should be explored 
in more extensive studies on OnabotulinumtoxinA treatment in CM [51]. 
Looking at previous literature, Wieser et al. (2011) reported that dysfunctional coping, 
characterized by fear and avoidance, is frequently used by headache patients [52]. Only a third of all 
patients in this cross-sectional study on pain coping behavior in patients with migraine and tension-
type headache used positive coping strategies with flexible reactions to pain [52]. Russo et al. (2019), 
in their cross-sectional study, recruited sixty-one patients with migraine without aura who completed 
three self-reported questionnaires assessing coping strategies [24]. Results suggested that migraine 
patients showed a low tendency to “turning to religion” approach than healthy controls; however, 
they did not differ on other coping strategies than healthy controls. Indeed, they did not perceive 
daily living as more stressful than healthy controls. Due to the sample characteristics and study 
design, it is not possible to compare our data with those reported by Russo et al. (2019). Our study 
confirms that coping strategies used by patients with CM are comparable to the general population, 
observing a slightly higher use of social support and lower use of problem-oriented coping [28]. 
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Interestingly, findings suggest that specific coping strategies might be related to different acute 
medication management (i.e., NSAIDs and triptans). Note that patients were free for choice in the 
acute medications use. Moreover, they were invited to respond to self-administered questionnaires, 
without any specific instruction on coping strategies or self-efficacy; these concepts were described 
in terms of usual behaviour in dealing with problems or pain to which patients had to respond by 
choosing the answer that better fitted for them. Our data showed that the overall analgesic 
consumption at baseline was positively correlated with a positive attitude and problem-solving 
oriented attitude. However, when analgesic consumption decreased at T2, higher problem-solving 
coping strategies turned out to be significant only for NSAIDs consumption. In contrast, the increase 
of analgesic consumption at T1 and specifically, the increase of triptans consumption both at T1 and 
T2 was related to higher avoidance coping strategies. Considering that the individual attempt to use 
cognitive and behavioural strategies to manage demands or stress (coping) has been poorly 
investigated in CM population attending prophylactic treatment and the complexity of CM, the 
current explorative results should be confirmed in a more extensive study. 
To sum up, our findings support the need for patients with CM for a management approach 
following the bio-psycho-social model. For an appropriate clinical practice during the 
OnabotulinumtoxinA prophylactic treatment, we recommend an integrated approach, including 
clinical psychologists working in collaboration with the Neurorehabilitation professionals, to assess 
psychological needs and profiles. The observed associations between coping strategies, CM disability 
and pharmacological management highlight the importance of introducing and tailoring 
psychological interventions considering different psychological factors, including coping strategies. 
Therefore, the current findings, although being explorative, reinforce the need for using a 
multidisciplinary approach to implement tailored brief psychological interventions aiming at 
reducing psychological distress and improving functional coping strategies and self-efficacy in the 
CM management. As regards the psychological treatment in the neurorehabilitation setting, different 
approaches, such as cognitive-behavioural, mindfulness, relaxation and biofeedback approaches, 
have been studied and reviewed resulting valid and safe interventions; and they should be 
introduced and used in the management of patients with headache [45]. Although these approaches 
vary somewhat, they have all shown to influence maladaptive behaviours and ways of thinking that 
contribute to headache-related burden and pain [43,44]. 
The limitations of our study are the lack of i) follow-up assessments about the psychological 
outcomes, ii) a control group drug naïve for OnabotulinumtoxinA prophylactic treatment, iii) data 
on the pre-prophylactic psychological profile. Additionally, the sample was small, and results were 
based mainly on correlations, which allow only a preliminary exploration of data. Further studies on 
larger samples of patients should consider these limits and introduce the evaluation of all the clinical 
and psychological data along with different treatment phases. Furthermore, our sample was mainly 
composed of females, although this is in line with the significant prevalence of CM among women. 
Finally, both clinical and psychological data were self-reported. 
Future studies should investigate the impact of the prophylactic treatment 
(OnabotulinumtoxinA or monoclonal antibodies) on the overall status of the patient, to repeat 
psychological assessment after the first three OnabotulinumtoxinA administration treatment cycles 
and to examine the combined effects of prophylactic treatment and psychological approaches (e.g., 
cognitive-behavioural therapy). 
4. Conclusions 
Our study supports that migraine has a multifaceted pathophysiology and suggests that specific 
sub-population of patients with CM undergoing OnabotulinumtoxinA prophylaxis might take 
advantage of specific psychological assessment to evaluate psychological profiles relevant to the 
management of disease. The applicability of our observations in clinical practice requires a 
multidisciplinary context with the strict collaboration of specialist in neurology, clinical psychology 
and neurorehabilitation. 
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5. Materials and Methods  
5.1. Study Design and Setting 
A prospective observational cohort study was performed from March 2018 to February 2019. 
The study is part of to the project “EXploring PsychoLOgical needs of patients with chronic pain 
attending neuroREhabilitation services” (EXPLORE) involving the Neurorehabilitation Unit and the 
Clinical Psychology Unit of the Verona University Hospital and the Neurology Unit of the Sacro 
Cuore Hospital in Negrar (north Verona). Outpatients with a confirmed diagnosis of CM made by a 
neurologist according to the Classification ICHD-III (beta) and eligible to OnabotulinumtoxinA 
prophylaxis were recruited [2,10]. OnabotulinumtoxinA injections were performed at the 
Neurorehabilitation Unit (AOUI Verona). After the visit, the patients have been informed about the 
EXPLORE project and asked to participate. After signing written informed consent, included patients 
filled out psychological questionnaires. Conversely, demographic and clinical data were collected 
from the medical charts according to clinical practice. The study design is presented in Figure 1. 
 
Figure 2. Study design. Patients underwent OnabotulinumtoxinA injection according to the 
PREEMPT protocol every 12 weeks. The headache diary was completed monthly during the study 
period. Clinical assessments were performed at T0, T1 and T2. Psychological assessment was 
performed at T0. 
5.2. Participants 
Inclusion criteria were: age ≥ 18 years, diagnosis of CM according to the Classification ICHD-III 
(beta) [2]; ineffective assumption of at least three different drug classes recommended by the 
International Guidelines of Migraine treatment [10]; undergoing the prophylactic treatment with 
OnabotulinumtoxinA because intolerance to/inefficacy of primary prophylaxis treatment; diagnosis 
of other primary headaches. 
Exclusion criteria were contraindications to prophylactic treatment using OnabotulinumtoxinA; 
the presence of other neurologic disturbances that can cause migraine; incomplete diary compiling 
in the 12 weeks before the enrolment; lack of consent to perform the psychological assessment. 
The EXPLORE project was performed according to the latest version of the Declaration of 
Helsinki and approved by the Ethics Committee of the AOUI of Verona (approval date: 17 January 
2018, 1630CESC, Prog. n. 14112).  
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5.3. Measures. 
5.3.1. Clinical and Demographic Characteristics 
Patients recorded headache characteristics using consecutive monthly headache diaries 
referring in the past three months before the recruitment in the study (T0), when the psychological 
assessment was performed and continued throughout the study period (T1, T2). 
From the headache diaries the following outcomes were recorded: the Headache Index (HI) 
calculated as the number of headache/migraine days over one month of observation; the intensity of 
pain calculated as the number of headache/migraine days with mild, moderate and severe pain over 
the period of observation; the total analgesic consumption (AC) calculated as the number of total 
analgesics taken during one-month period; the consumption of NSAIDs (NSAIDs C) and triptans 
(Triptans C) calculated as the number of NSAID and triptans taken in the reference period, 
respectively. 
5.3.2. Headache-Related Disability 
At every injection session (T0, T1, T2), the headache-related disability was assessed using the 
Headache Impact Test (HIT-6) [53–55]. The HIT-6 is a six-item validated questionnaire measuring the 
headache severity and its adverse impact on social functioning, role functioning, vitality, cognitive 
functioning and psychological distress (higher = worse performance; 60 = severe impact; 56–59 
substantial impact; 50–55 some impact; ≤ 49 little to no impact). The within-person Minimally 
Important Change (MIC) was estimated to be between −2.5 points (mean change approach) and −6 
points (Receiver Operating Characteristic - ROC curve approach) [54]. 
At T0, the Migraine Disability Assessment (MIDAS) Questionnaire was administered to assess 
the disability induced by the headache during the previous three months. It is a brief, self-
administered questionnaire including five items which examine the disability in three fields of daily-
life: either school or work, household work, and either family or social or leisure activities. Two 
additional questions concern: i) the number of days with headache; ii) the pain of headache attacks 
(on a 0–10 scale) [56]. 
5.3.3. Psychological Outcomes 
The psychological assessment in the EXPLORE project was performed at T0 during the same 
visit to the OnabotulinumtoxinA treatment session and included a battery of questionnaires. The 
psychological tools considered in this study are: the General Self efficacy (GSE) scale; the Coping 
Orientation to Problems Experienced (COPE); the Symptom Checklist-90 (SCL-90-R) questionnaire 
of which the global severity index (GSI) is reported (average of all SCL-90-R responses) [47,57].  
The General Self Efficacy Scale (GSE) is a measure of people’s “optimistic self-beliefs to cope 
with a variety of difficult demands in life”. It consists of 10 items rated on a scale of 1 (not at all true) 
to 4 (exactly true). The total range between 10 and 40, with higher scores, correspond to greater levels 
of perceived self-efficacy [47,58]. 
The new Italian version of the COPE was used to measure strategies by individuals to cope with 
problems and stress [28]. It is a 60-item self-report measure exploring the following independent 
coping strategies: positive attitude, social support, problem-solving, avoidance strategies, and 
turning to religion. Each item is answered on a four-point Likert-type scale ranging from “I usually 
do not do this at all” to “I usually do this a lot.”  
5.4. OnabotulinumtoxinA Treatment 
All patients were undergoing OnabotulinumtoxinA prophylaxis according to the international 
guidelines based on the PREEMPT injection protocol. A total of 195 U was injected every 12 weeks 
into 39 injection sites (each injection was 5U/0.1 mL) [8,10]. The same expert clinician (MG) performed 
the treatments as for the fixed-dose paradigm consisting of 155U administered to 31 injection sites 
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across seven head and neck muscles. Besides, 40 U OnabotulinumtoxinA was administered to 8 
additional injection sites across three head and neck muscles using a “follow-the-pain” approach. 
5.5. Study Size 
So far, literature has investigated mainly mood and anxiety disorders in patients with CM under 
Onabotulinumtoxin prophylaxis. Due to the explorative nature of the EXPLORE project and to the 
lack of studies that have evaluated a broader range of psychological aspects, including self-efficacy 
perception and coping strategies, it was not possible to calculate the sample size. Therefore, we 
decided to recruit 40 patients based on the recruitment capability over 11 months at the 
Neurorehabilitation Unit in the Verona University Hospital. 
5.6. Statistical Analysis 
Descriptive statistics included means, standard deviation and percentage calculation. The 
Shapiro–Wilk test was used to test data distribution. Non-parametric tests were used for inferential 
statistics. The Friedman test was used to test for repeated measures differences. Post hoc analysis 
with Wilcoxon signed-rank tests was conducted with a Bonferroni correction applied, resulting in a 
significance level set at p ≤ 0.025. A Spearman’s rank-order correlation was run to determine the 
relationship between the psychological outcomes and acute medication consumption and HI. For this 
purpose, the changes of the score (Δ) between T1-T0 and T2-T0 were computed in the analgesic 
consumption, NSAIDs consumption and triptans consumption. Higher values corresponded to 
increased medication consumption at T1 and T2 concerning T0. The level of significance was set p ≤ 
0.05. Software statistics SPSS 20.0 (IBM SPSS Statistics, Version 22.0, 2013, Armonk, NY, USA). 
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